Compare FCAP & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FCAP | STTK |
|---|---|---|
| Founded | 1891 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 125.9M | 119.0M |
| IPO Year | 1999 | 2020 |
| Metric | FCAP | STTK |
|---|---|---|
| Price | $48.15 | $3.06 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | 4.0K | ★ 224.7K |
| Earning Date | 01-23-2026 | 11-06-2025 |
| Dividend Yield | ★ 2.44% | N/A |
| EPS Growth | ★ 25.19 | N/A |
| EPS | ★ 4.41 | N/A |
| Revenue | ★ $47,323,000.00 | $1,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $11.52 | ★ N/A |
| Revenue Growth | ★ 15.22 | N/A |
| 52 Week Low | $28.50 | $0.69 |
| 52 Week High | $53.85 | $3.12 |
| Indicator | FCAP | STTK |
|---|---|---|
| Relative Strength Index (RSI) | 69.75 | 79.66 |
| Support Level | $47.48 | $1.93 |
| Resistance Level | $50.95 | $2.18 |
| Average True Range (ATR) | 0.99 | 0.20 |
| MACD | 0.37 | 0.12 |
| Stochastic Oscillator | 97.55 | 98.42 |
First Capital Inc is the financial holding company of First Harrison Bank. Through its subsidiary, it operates as a federally-chartered savings bank that provides banking services to individuals and business customers across locations in America. The bank offers various loans which include residential loans, construction loans, commercial real estate loans and commercial business loans. It also provides consumer loans such as home equity and second mortgage loans, and automobile and truck loans.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.